Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker BIOA
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | Shane Barton Principal Accounting Officer | BIOA BioAge Labs, Inc. | Sale | 20,216 | $25.19 | $509.2K Sale | Form 4 ↗ |
| Jun 29, 2026 | Shane Barton Principal Accounting Officer | BIOA BioAge Labs, Inc. | Sale | 42,350 | $25.21 | $1.1M Sale | Form 4 ↗ |
| Apr 1, 2026 | Paul D. Rubin Chief Medical Officer | BIOA BioAge Labs, Inc. | Sale | 8,820 | $17.81 | $157.1K Sale | Form 4 ↗ |
| Mar 2, 2026 | Paul D. Rubin Chief Medical Officer | BIOA BioAge Labs, Inc. | Sale | 7,433 | $20.30 | $150.9K Sale | Form 4 ↗ |
| Feb 2, 2026 | Paul D. Rubin Chief Medical Officer | BIOA BioAge Labs, Inc. | Sale | 7,433 | $18.75 | $139.4K Sale | Form 4 ↗ |
| Jan 13, 2026 | Kristen Fortney Chief Executive Officer, Director | BIOA BioAge Labs, Inc. | Sale | 233,107 | $18.12 | $4.2M Sale | Form 4 ↗ |
| Jan 13, 2026 | Dov A. Goldstein MD Chief Financial Officer | BIOA BioAge Labs, Inc. | Sale | 1,923 | $21.08 | $40.5K Sale | Form 4 ↗ |
| Jan 13, 2026 | Dov A. Goldstein MD Chief Financial Officer | BIOA BioAge Labs, Inc. | Sale | 11,663 | $20.54 | $239.6K Sale | Form 4 ↗ |
| Jan 13, 2026 | Dov A. Goldstein MD Chief Financial Officer | BIOA BioAge Labs, Inc. | Sale | 4,440 | $19.45 | $86.4K Sale | Form 4 ↗ |
| Jan 13, 2026 | Dov A. Goldstein MD Chief Financial Officer | BIOA BioAge Labs, Inc. | Sale | 8,974 | $18.43 | $165.4K Sale | Form 4 ↗ |
| Jan 2, 2026 | Paul D. Rubin Chief Medical Officer | BIOA BioAge Labs, Inc. | Sale | 7,433 | $12.85 | $95.5K Sale | Form 4 ↗ |
| Dec 9, 2025 | Paul D. Rubin Chief Medical Officer | BIOA BioAge Labs, Inc. | Sale | 18,000 | $12.00 | $216.0K Sale | Form 4 ↗ |
| Dec 4, 2025 | Paul D. Rubin Chief Medical Officer | BIOA BioAge Labs, Inc. | Sale | 68,897 | $10.19 | $702.1K Sale | Form 4 ↗ |
| Oct 3, 2024 | Vijay Satyanand Pande Director | BIOA BioAge Labs, Inc. | Buy | 25,306 | $19.90 | $503.6K Buy | Form 4 ↗ |
| Oct 2, 2024 | Vijay Satyanand Pande Director | BIOA BioAge Labs, Inc. | Buy | 67,096 | $19.73 | $1.3M Buy | Form 4 ↗ |
| Oct 1, 2024 | Vijay Satyanand Pande Director | BIOA BioAge Labs, Inc. | Buy | 126,793 | $19.73 | $2.5M Buy | Form 4 ↗ |
| Sep 27, 2024 | Rekha Hemrajani Director | BIOA BioAge Labs, Inc. | Buy | 3,000 | $18.00 | $54.0K Buy | Form 4/A ↗ |
| Sep 27, 2024 | Shane Barton Principal Accounting Officer | BIOA BioAge Labs, Inc. | Buy | 2,632 | $18.00 | $47.4K Buy | Form 4 ↗ |
| Sep 27, 2024 | Bihua Chen | BIOA BioAge Labs, Inc. | Buy | 450,000 | $18.00 | $8.1M Buy | Form 4 ↗ |
19 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:44 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances